Navigation Links
Aerovance Secures $38 Million in Equity Financing
Date:4/7/2009

advance Aerovant into the Phase IIb study, AeroTrial(TM), to evaluate the compound's safety and efficacy in patients living with uncontrolled asthma."

We welcome both Alain Schreiber and Ann Hanham to our board of directors. They have extensive drug development and commercialization expertise that complement the experience of our existing board members and senior management team. On behalf of our board, I would like to thank Hingge Hsu for his numerous contributions and valuable guidance since Aerovance's formation."

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004. Aerovant is currently in a Phase IIb clinical trial for the treatment of uncontrolled asthma.

AeroTrial is a late-stage clinical study using a dry powder formulation and follows positive clinical data from two Phase IIa studies in which Aerovant demonstrated significant benefit in asthmatics who were experimentally challenged with inhaled allergen (The Lancet 2007, 370: 1422-31). The dry powder formulation that will be used in AeroTrial was well tolerated in a recently completed Phase I study in asthmatics. By using a medication based on a protein occurring naturally in the body, AeroTrial seeks a non-steroidal solution to getting control of asthma. For more information, visit www.aerotrial.com.

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit www.aerovance.com.

    Contact: A
'/>"/>
SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
2. Aerovance Secures $20 Million in Debt Financing
3. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
4. Pearl Therapeutics Secures $8 Million in Debt Financing
5. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
6. Sopherion Therapeutics Secures $55 Million in Series C Funding
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
9. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
10. Pharmacyclics Secures $5.0 Million in Debt Financing
11. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a company overview at the ... a.m. ET in Boston, MA. ... on the "Investors & Media" section of the Company,s website, ... Isis website within 48 hours and will be archived for ...
(Date:10/30/2014)... 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... conference call and live audio webcast on Thursday, November ... third quarter 2014 financial results. Interested participants ... (888) 347-1165 for domestic callers or (412) 902-4276 for ... under the investor relations section of the Regado website ...
(Date:10/30/2014)... DENVER (Oct. 29, 2014) – The severe flooding that ... have been less destructive if the bridges, roads and ... a new study from the University of Colorado Denver. ... of infrastructure," said Jimmy Kim, PhD, associate professor of ... and Applied Science and lead author the study. "There ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... HILL, N.C., Jan. 12, 2011 Cempra Pharmaceuticals ... of solithromycin (CEM-101), the first fluoroketolide antibiotic, at ... Advanced Research and Development Authority (BARDA) industry day ...   Solithromycin is a clinical-stage fluoroketolide ...
... Jan. 11, 2011 Fred Hutchinson Cancer Research Center ... Robert Eisenman, Ph.D., a molecular biologist and geneticist, have ... Advancement of Science, or AAAS. Election as a fellow ... peers. Brent, a member of the Hutchinson ...
... 2011 Regenicin, Inc. (OTC Bulletin Board: ... of regenerative cell therapies to restore the health of ... annual OneMedForum at the Sir Francis Drake Hotel in ... McCoy, will present Regenicin,s core business model and strategic ...
Cached Biology Technology:Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 2Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day 3Roger Brent and Robert Eisenman Named AAAS Fellows 2Roger Brent and Robert Eisenman Named AAAS Fellows 3Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2
(Date:10/29/2014)... . Meiosis ... at the Max F. Perutz Laboratories (MFPL) of the ... dived into the process of meiosis in specific plant ... of the standard meiotic phases. The researchers describe the ... . , Meiosis is the two-step series of cell ...
(Date:10/29/2014)... of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen records ... into a human-readable text developed in manuscript within the ... to study the species distributions of ten Nearctic species ... is originally designed to support the generation and application ...
(Date:10/29/2014)... organisms in the living world compete with members ... in how much they invest into their competitive ... to get access to high-quality resources, while others ... of the lower-quality resources that are left over ... animal and human societies seems to fluctuate considerably ...
Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Evolution of competitiveness 2Evolution of competitiveness 3
... Many plants produce toxic chemicals to protect themselves ... flower structures that prevent pollinators such as bees from ... evidence that flowering plants might also use chemical defences ... are published next week in the British Ecological Society,s ...
... MA - It is estimated that up to 10 ... of renal disease, with 450,000 patients with end stage ... Women,s Hospital, Massachusetts General Hospital and the University of ... be transplanted from one fish to another to regenerate ...
... students to ultimately provide quality patient care medical schools should ... the core disciplines of medicine, according to a study in ... College of Radiology ( www.jacr.org ). Physiology is the ... is vital that medical schools provide first-rate physiology education for ...
Cached Biology News:Secret life of bees now a little less secret 2Researchers unlock the potential for exploring kidney regeneration 2